Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthequity (HQY) Research & Development (2016 - 2026)

Healthequity (HQY) has 13 years of Research & Development data on record, last reported at $65.9 million in Q4 2025.

  • For Q4 2025, Research & Development rose 9.52% year-over-year to $65.9 million; the TTM value through Oct 2025 reached $256.8 million, up 11.61%, while the annual FY2025 figure was $239.5 million, 9.46% up from the prior year.
  • Research & Development reached $65.9 million in Q4 2025 per HQY's latest filing, up from $64.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $65.9 million in Q4 2025 and bottomed at $32.3 million in Q1 2021.
  • Average Research & Development over 5 years is $51.7 million, with a median of $54.0 million recorded in 2023.
  • Peak YoY movement for Research & Development: rose 2.55% in 2021, then skyrocketed 42.11% in 2022.
  • A 5-year view of Research & Development shows it stood at $38.1 million in 2021, then rose by 28.42% to $48.9 million in 2022, then increased by 13.75% to $55.6 million in 2023, then grew by 8.23% to $60.2 million in 2024, then increased by 9.52% to $65.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $65.9 million in Q4 2025, $64.8 million in Q3 2025, and $61.4 million in Q2 2025.